生物谷(833266) - 2025 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter of 2025 was CNY 92,118,348.63, down 40.35% year-on-year [10]. - Net profit attributable to shareholders for the first quarter of 2025 was a loss of CNY 16,768,203.83, representing a decline of 259.25% compared to the same period last year [10]. - Basic earnings per share for the first quarter of 2025 was -CNY 0.14, a decrease of 275.00% year-on-year [10]. - The company's cash flow from operating activities for the first quarter of 2025 was -CNY 24,104,184.81, a decline of 144.49% compared to the previous year [10]. - Total operating revenue for Q1 2025 was CNY 92,118,348.63, a decrease from CNY 154,441,052.85 in Q1 2024 [50]. - Net profit for Q1 2025 was a loss of CNY 16,768,203.83, while Q1 2024 reported a net profit of CNY 10,529,264.31 [51]. - The total comprehensive income for Q1 2025 was a loss of ¥17,389,376.69, compared to a comprehensive income of ¥9,570,421.92 in Q1 2024 [54]. Assets and Liabilities - Total assets as of March 31, 2025, were CNY 1,112,800,070.14, a decrease of 2.82% compared to the end of the previous year [10]. - The asset-liability ratio for the consolidated entity was 18.38%, down from 19.21% at the end of the previous year [10]. - Total current assets decreased from ¥546,033,405.54 in 2024 to ¥513,462,121.01 in 2025, a decline of approximately 5.93% [44]. - Total liabilities decreased from ¥219,970,089.73 in 2024 to ¥204,490,988.67 in 2025, a reduction of approximately 7.06% [46]. - Total equity attributable to shareholders decreased from ¥925,077,285.30 in 2024 to ¥908,309,081.47 in 2025, a decline of about 1.81% [46]. Shareholder Information - The largest shareholder, Shanghai Xinhong Pharmaceutical Co., Ltd., holds 32,851,219 shares, accounting for 26.49% of total shares [20]. - The total number of shareholders with more than 5% ownership is 10, collectively holding 65,807,461 shares, which is 53.06% of total shares [21]. - The total number of unrestricted shares increased from 76,935,090 to 76,990,252, representing a change of 55,162 shares, which is an increase of 0.07% [20]. - The total number of restricted shares decreased from 47,064,917 to 47,009,755, reflecting a change of -55,162 shares, which is a decrease of 0.15% [20]. Cash Flow and Expenses - The company reported a total cash inflow from operating activities of ¥106,460,668.56 in Q1 2025, compared to ¥189,066,154.08 in Q1 2024, a decrease of 43.6% [57]. - The cash flow from operating activities for Q1 2025 was negative at -¥24,104,184.81, contrasting with a positive cash flow of ¥54,184,916.38 in Q1 2024 [56]. - The company incurred sales expenses of ¥41,526,778.03 in Q1 2025, a decrease of 54.7% from ¥91,567,552.81 in Q1 2024 [53]. - Research and development expenses were ¥2,915,757.96 in Q1 2025, slightly up from ¥2,697,325.40 in Q1 2024, reflecting an 8.1% increase [53]. Related Party Transactions and Legal Issues - The company has engaged in related party transactions amounting to ¥166,696.74 for utility payments to Yunnan Biopharmaceutical Co., Ltd. and ¥754,652.00 for product sales to Longyan Pianzaihuang Hongren Pharmaceutical Co., Ltd. [35]. - The company has filed a civil lawsuit against Jinsha River and Lin Yanhe regarding the fund occupation, which is currently in the legal process [30]. - The company has maintained communication with Jinsha River and Lin Yanhe to resolve the fund occupation issue [38]. - The Guangdong High Court upheld the lower court's ruling, concluding the case regarding the fund occupation [31]. Fund Occupation and Recovery Efforts - The company reported that the controlling shareholder, Shenzhen Jinsanjiang Investment Co., Ltd., occupied funds totaling 257 million yuan, which have not yet been repaid [28]. - As of March 31, 2025, the controlling shareholder has repaid 20 million yuan of the occupied funds [29]. - The company has taken measures to recover the remaining occupied funds of 257 million yuan and corresponding returns [29]. - The company has implemented measures to prevent dividend distribution to Jinsha River and Lin Yanhe until they fulfill their commitments [40]. - The company has accrued bad debts totaling ¥195.32 million due to unreturned funds [32].